Show simple item record

dc.contributor.authorCadenas-Fernández, Jennifer
dc.contributor.authorAhumada-Pascual, Pablo
dc.contributor.authorSanz Andreu, Luis 
dc.contributor.authorVelasco Criado, Ana Purificación 
dc.date.accessioned2024-01-25T08:47:19Z
dc.date.available2024-01-25T08:47:19Z
dc.date.issued2021
dc.identifier.issn1381-6128
dc.identifier.urihttp://hdl.handle.net/10366/154657
dc.description.abstractMammalian nervous systems depend crucially on myelin sheaths covering the axons. In the central nervous system, myelin sheaths consist of lipid structures that are generated from the membrane of oligodendro-cytes (OL). These sheaths allow fast nerve transmission, protect axons and provide them metabolic support. In response to specific traumas or pathologies, these lipid structures can be destabilized and generate demyelinat-ing lesions. Multiple sclerosis (MS) is an example of a demyelinating disease in which the myelin sheaths sur-rounding the nerve fibers of the brain and spinal cord are damaged. MS is the leading cause of neurological disability in young adults in many countries, and its incidence has been increasing in recent decades. Related to its etiology, it is known that MS is an autoimmune and inflammatory CNS disease. However, there are no effective treatments for this disease and the immunomodulatory therapies that currently exist have proven limited success since they only delay the progress of the disease. Nowadays, one of the main goals in MS research is to find treatments which allow the recovery of neurological disabilities due to demyelination. To this end, different approaches, such as modulating intracellular signaling or regulating the lipid metabolism of OLs, are being considered. Here, in addition to immunosuppressive or immunomodulatory drugs that reduce the immune response against myelin sheaths, we review a diverse group of drugs that promotes endogenous remyelination in MS patients and their use may be interesting as potential therapeutic agents in MS disease. To this end, we compile specific treatments against MS that are currently in the market with remyelination strategies that have entered into human clinical trials for future reparative MS therapies. The method used in this study is a systematic literature review on PubMed, Web of Science and Science Direct databases up to May 31, 2020. To narrow down the search results in databases, more specific keywords, such as “myelin sheath”, “remyelination”, “de-myelination”, “oligodendrocyte” and “lipid synthesis” were used to focus the search. We preferred papers pub-lished after January 2015, but did not exclude earlier seminal papers.es_ES
dc.format.mimetypeapplicatio/pdf
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMultiple sclerosis
dc.subjectMyelin sheath
dc.subjectRemyelination
dc.subjectDemyelination
dc.subjectOligodendrocyte
dc.subjectLipid metabolism
dc.titleRecent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttp://dx.doi.org/10.2174/1381612827666210127121829
dc.subject.unesco3207.11 Neuropatología
dc.identifier.doi10.2174/1381612827666210127121829
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.journal.titleCurrent Pharmaceutical Designes_ES
dc.volume.number27es_ES
dc.issue.number30es_ES
dc.page.initial3273es_ES
dc.page.final3280es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional